首页 > 最新文献

Journal of Oncology Pharmacy Practice最新文献

英文 中文
Initial real-world experience with ribociclib in advanced breast cancer.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-17 DOI: 10.1177/10781552251317962
Azhar Nawaz, Jamal Zekri, Haleem Rasool, Refaei Ibrahim

Purpose: CDK4/6 inhibitors, such as ribociclib, are recommended in combination with hormonal therapy to treat advanced/metastatic hormone receptor-positive, HER2-negative breast cancer. The objectives of this study are to evaluate the therapeutic outcome and tolerance of ribociclib in patients treated at our institution.

Methods: The initial cohort of patients who received >1 cycle of ribociclib between December 2018 and March 2022 were included. Rates of adverse events (AEs) related dose reduction and discontinuation of ribociclib were used as a surrogate marker for intolerance.

Results: Sixty-eight female patients were included. Ribociclib was administered with letrozole or fulvestrant in the first-, second-, third-, and fourth-line palliative hormonal therapy settings in 29 (42.6%), 26 (38.2%), 12 (17.6%) and 1 (1.5%) patients respectively. Adverse events (AEs) related dose reduction was reported in 30 (44%) patients. Ribociclib was permanently discontinued in 42/68 (61.8%) patients [Disease progression 33/68 (48.5%) and AEs 9 (13.2%)]. Objective response was documented in 10/61 (16.4%) evaluable patients. The median progression free survival (PFS) was 18 months (95% CI: 11.7-24.3). The median overall survival (OS) was not reached and 84% of patients were alive at 3 years.

Conclusions: Although objective response rates were modest in this mixed cohort of heavily pretreated patients, ribociclib combined with letrozole or fulvestrant has shown robust PFS and OS in real-world practice. AEs related treatment discontinuation rate is higher than that reported in clinical trials with stringent inclusion criteria.

{"title":"Initial real-world experience with ribociclib in advanced breast cancer.","authors":"Azhar Nawaz, Jamal Zekri, Haleem Rasool, Refaei Ibrahim","doi":"10.1177/10781552251317962","DOIUrl":"https://doi.org/10.1177/10781552251317962","url":null,"abstract":"<p><strong>Purpose: </strong>CDK4/6 inhibitors, such as ribociclib, are recommended in combination with hormonal therapy to treat advanced/metastatic hormone receptor-positive, HER2-negative breast cancer. The objectives of this study are to evaluate the therapeutic outcome and tolerance of ribociclib in patients treated at our institution.</p><p><strong>Methods: </strong>The initial cohort of patients who received >1 cycle of ribociclib between December 2018 and March 2022 were included. Rates of adverse events (AEs) related dose reduction and discontinuation of ribociclib were used as a surrogate marker for intolerance.</p><p><strong>Results: </strong>Sixty-eight female patients were included. Ribociclib was administered with letrozole or fulvestrant in the first-, second-, third-, and fourth-line palliative hormonal therapy settings in 29 (42.6%), 26 (38.2%), 12 (17.6%) and 1 (1.5%) patients respectively. Adverse events (AEs) related dose reduction was reported in 30 (44%) patients. Ribociclib was permanently discontinued in 42/68 (61.8%) patients [Disease progression 33/68 (48.5%) and AEs 9 (13.2%)]. Objective response was documented in 10/61 (16.4%) evaluable patients. The median progression free survival (PFS) was 18 months (95% CI: 11.7-24.3). The median overall survival (OS) was not reached and 84% of patients were alive at 3 years.</p><p><strong>Conclusions: </strong>Although objective response rates were modest in this mixed cohort of heavily pretreated patients, ribociclib combined with letrozole or fulvestrant has shown robust PFS and OS in real-world practice. AEs related treatment discontinuation rate is higher than that reported in clinical trials with stringent inclusion criteria.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251317962"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-13 DOI: 10.1177/10781552241313057
Rosalaura Villarreal-González, Ana Karen Treviño-Morales, Diana Cadenas-García, Ángel López-Galindo, Oscar Vidal-Gutiérrez

Introduction: Urothelial carcinoma is the prevailing type of bladder cancer, characterized by expression of the programed death-ligand-1-protein (PD-L1). Avelumab is an anti-PD-L1 monoclonal antibody used in urothelial carcinoma. It is associated with an incidence of 47.4% and 25.2% in grade 3 adverse events or greater, respectively; gastrointestinal symptoms and cutaneous affections are the most common.

Case report: A 52-year-old male with a history of rectal cancer and non-muscle-invasive bladder carcinoma. PET/CT revealed adenopathies in the pelvic region, the biopsy confirmed metastatic urothelial carcinoma. Next PET/CT indicated progression. Treatment with Cisplatin + Gemcitabine led to complete response after 4 cycles. Maintenance with Avelumab was indicated. Fifteen minutes after the first Avelumab administration, the patient experienced hypotension, presyncope, skin itching, and nasal congestion. Epinephrine, hydrocortisone, and physiological solution were administered, with resolution of symptoms.

Management & outcome: Since Avelumab is first-line maintenance therapy in this patient, a desensitization protocol was performed with (3-bag, 12-steps). The patient was premedicated with acetaminophen and chlorpheniramine. The protocol was successfully completed without hypersensitivity reactions for 6 cycles.

Discussion: Patients with hypersensitivity reactions to their first line of treatment are challenged to continue the best approach. We detail the case of a patient diagnosed with metastatic urothelial carcinoma who underwent a desensitization protocol for Avelumab after presenting a severe allergic reaction. The patient tolerated Avelumab throughout the protocol with no complications, achieving the total dosage for his maintenance therapy; drug desensitization is a safe and effective procedure in patients with hypersensitivity reactions to their first-line treatment.

{"title":"Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.","authors":"Rosalaura Villarreal-González, Ana Karen Treviño-Morales, Diana Cadenas-García, Ángel López-Galindo, Oscar Vidal-Gutiérrez","doi":"10.1177/10781552241313057","DOIUrl":"https://doi.org/10.1177/10781552241313057","url":null,"abstract":"<p><strong>Introduction: </strong>Urothelial carcinoma is the prevailing type of bladder cancer, characterized by expression of the programed death-ligand-1-protein (PD-L1). Avelumab is an anti-PD-L1 monoclonal antibody used in urothelial carcinoma. It is associated with an incidence of 47.4% and 25.2% in grade 3 adverse events or greater, respectively; gastrointestinal symptoms and cutaneous affections are the most common.</p><p><strong>Case report: </strong>A 52-year-old male with a history of rectal cancer and non-muscle-invasive bladder carcinoma. PET/CT revealed adenopathies in the pelvic region, the biopsy confirmed metastatic urothelial carcinoma. Next PET/CT indicated progression. Treatment with Cisplatin + Gemcitabine led to complete response after 4 cycles. Maintenance with Avelumab was indicated. Fifteen minutes after the first Avelumab administration, the patient experienced hypotension, presyncope, skin itching, and nasal congestion. Epinephrine, hydrocortisone, and physiological solution were administered, with resolution of symptoms.</p><p><strong>Management & outcome: </strong>Since Avelumab is first-line maintenance therapy in this patient, a desensitization protocol was performed with (3-bag, 12-steps). The patient was premedicated with acetaminophen and chlorpheniramine. The protocol was successfully completed without hypersensitivity reactions for 6 cycles.</p><p><strong>Discussion: </strong>Patients with hypersensitivity reactions to their first line of treatment are challenged to continue the best approach. We detail the case of a patient diagnosed with metastatic urothelial carcinoma who underwent a desensitization protocol for Avelumab after presenting a severe allergic reaction. The patient tolerated Avelumab throughout the protocol with no complications, achieving the total dosage for his maintenance therapy; drug desensitization is a safe and effective procedure in patients with hypersensitivity reactions to their first-line treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241313057"},"PeriodicalIF":1.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis. 贝伐单抗治疗对卵巢癌患者高血压发病率的影响:系统回顾和荟萃分析。
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-11 DOI: 10.1177/10781552241307868
Xiaoyan Zhang, Jumei Hu, Xijing Fan, Qiaoqiao Chen, Danjun Zheng, Minjuan Huang, Yuanqing Xu

Introduction: This study aims to evaluate the effect of bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer.

Methods: A comprehensive search of PubMed, Scopus, Embase, Cochrane, Web of Science, and Google Scholar databases was conducted until August 2024. We included only randomized clinical trials that compared ovarian cancer patients treated with Bevacizumab to those treated with other therapies. The primary outcome was the relative risk (RR) of developing hypertension, stratified by grade. Statistical analyses were performed using a random-effects model to account for heterogeneity between studies. Subgroup analyses were conducted based on hypertension severity (grade ≥2 and grade ≥3) and disease stage. Sensitivity analyses and publication bias assessments were also performed.

Results: A total of 11 randomized trials were included, comprising 5212 patients. The meta-analysis revealed that patients receiving Bevacizumab had a significantly higher risk of hypertension compared to controls (RR = 2.91, 95% CI: 1.65-5.16, P = 0.0002). Subgroup analysis showed that the risk of grade ≥2 hypertension was 1.68 times higher (95% CI: 0.92-3.07), and grade ≥3 hypertension was 5.10 times higher (95% CI: 2.46-10.55) in the Bevacizumab group. Sensitivity analysis confirmed the robustness of these findings, and no significant publication bias was detected.

Conclusion: Bevacizumab treatment in ovarian cancer significantly increases the risk of hypertension, particularly severe hypertension (grade ≥3). These findings underscore the need for vigilant blood pressure monitoring and management in patients receiving Bevacizumab to mitigate cardiovascular complications and optimize treatment outcomes.

{"title":"The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis.","authors":"Xiaoyan Zhang, Jumei Hu, Xijing Fan, Qiaoqiao Chen, Danjun Zheng, Minjuan Huang, Yuanqing Xu","doi":"10.1177/10781552241307868","DOIUrl":"https://doi.org/10.1177/10781552241307868","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the effect of bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Scopus, Embase, Cochrane, Web of Science, and Google Scholar databases was conducted until August 2024. We included only randomized clinical trials that compared ovarian cancer patients treated with Bevacizumab to those treated with other therapies. The primary outcome was the relative risk (RR) of developing hypertension, stratified by grade. Statistical analyses were performed using a random-effects model to account for heterogeneity between studies. Subgroup analyses were conducted based on hypertension severity (grade ≥2 and grade ≥3) and disease stage. Sensitivity analyses and publication bias assessments were also performed.</p><p><strong>Results: </strong>A total of 11 randomized trials were included, comprising 5212 patients. The meta-analysis revealed that patients receiving Bevacizumab had a significantly higher risk of hypertension compared to controls (RR = 2.91, 95% CI: 1.65-5.16, P = 0.0002). Subgroup analysis showed that the risk of grade ≥2 hypertension was 1.68 times higher (95% CI: 0.92-3.07), and grade ≥3 hypertension was 5.10 times higher (95% CI: 2.46-10.55) in the Bevacizumab group. Sensitivity analysis confirmed the robustness of these findings, and no significant publication bias was detected.</p><p><strong>Conclusion: </strong>Bevacizumab treatment in ovarian cancer significantly increases the risk of hypertension, particularly severe hypertension (grade ≥3). These findings underscore the need for vigilant blood pressure monitoring and management in patients receiving Bevacizumab to mitigate cardiovascular complications and optimize treatment outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241307868"},"PeriodicalIF":1.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
End-of-life symptoms and polypharmacy in lung and other cancer patients receiving palliative care in Turkey.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-04 DOI: 10.1177/10781552251316180
Vildan Kocatepe, Halide Fulya Uludağ Kızıltepe, Dilek Yildirim, Özlem Oruç

Introduction: Patients diagnosed with cancer are often prescribed a wide range of medicines. In this study, it was aimed at examining the end-of-life symptoms and polypharmacy status of patients hospitalized in the palliative care unit with the diagnosis of lung cancer and other cancers.

Methods: The data for the retrospective-descriptive study were obtained from hospital records and an automation system. The sample of the study included the data of all patients (n = 201) who were hospitalized in the palliative care unit between 2016-2021 in Turkey.

Results: The most common symptoms of end-of-life patients were dyspnea (85.1%) and pain (67.7%). The mean number of medications used by the patients on the day of death was 10.89 ± 3.16, it was 12.50 ± 3.11 on the third day before death, 13.24 ± 3.07 on the 6th day before death, 13.50 ± 3.03 on the 9th day before death. There was a statistically significant difference between the mean number of medications used by the patients according to the presence of dyspnea on the day of death (t = 1.997; p = .047) and pain on the day of death (t = 3.781; p = .001). There was a statistically significant difference between the mean number of medications used by the patients according to the presence of pain on the sixth day before death (t = 2.613; p = .010) and the ninth day before death (t = 2.940; p = .004).

Conclusion: The number of medications used by the patients decreased from the 9th day before death to the day of death and their polypharmacy status continued.

{"title":"End-of-life symptoms and polypharmacy in lung and other cancer patients receiving palliative care in Turkey.","authors":"Vildan Kocatepe, Halide Fulya Uludağ Kızıltepe, Dilek Yildirim, Özlem Oruç","doi":"10.1177/10781552251316180","DOIUrl":"https://doi.org/10.1177/10781552251316180","url":null,"abstract":"<p><strong>Introduction: </strong>Patients diagnosed with cancer are often prescribed a wide range of medicines. In this study, it was aimed at examining the end-of-life symptoms and polypharmacy status of patients hospitalized in the palliative care unit with the diagnosis of lung cancer and other cancers.</p><p><strong>Methods: </strong>The data for the retrospective-descriptive study were obtained from hospital records and an automation system. The sample of the study included the data of all patients (n = 201) who were hospitalized in the palliative care unit between 2016-2021 in Turkey.</p><p><strong>Results: </strong>The most common symptoms of end-of-life patients were dyspnea (85.1%) and pain (67.7%). The mean number of medications used by the patients on the day of death was 10.89 ± 3.16, it was 12.50 ± 3.11 on the third day before death, 13.24 ± 3.07 on the 6th day before death, 13.50 ± 3.03 on the 9th day before death. There was a statistically significant difference between the mean number of medications used by the patients according to the presence of dyspnea on the day of death (t = 1.997; p = .047) and pain on the day of death (t = 3.781; p = .001). There was a statistically significant difference between the mean number of medications used by the patients according to the presence of pain on the sixth day before death (t = 2.613; p = .010) and the ninth day before death (t = 2.940; p = .004).</p><p><strong>Conclusion: </strong>The number of medications used by the patients decreased from the 9th day before death to the day of death and their polypharmacy status continued.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316180"},"PeriodicalIF":1.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL).
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-03 DOI: 10.1177/10781552241313381
Baptiste Fulbert, Théo Vincent, Justine Clarenne, Imman Abdelouahab, Antoine Le Bozec, Eric Durot, Florian Slimano

Background: Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for Hematopoietic Stem Cell Transplantation (HSCT) may benefit from a second line anticancer drug regimen but real-life outcomes are lacking.

Objective: To describe the efficacity of 3 anticancer drug regimens (Gemcitabine and Oxaliplatin GEMOX; Ifosfamide and Etoposide IE; Cyclophosphamide, Etoposide, Procarbazine and Prednisone CEPP) combined with Rituximab (R-) in terms of progression-free (PFS) and overall survival (OS).

Patients: Retrospective study including R/R DLBCL patients HSCT ineligible who received at least one cycle of R-GEMOX, R-IE or R-CEPP between 2010 and 2022. Demographic, clinical, biological and survival data were collected. Univariate and multivariate analysis were performed to identify associated variables with survival outcomes.

Results: Sixty-two patients (median age 78 [40-102] with predominantly stage III-IV DLBCL (n = 49, 79%), non-germinal center-B like (n = 27, 44%) were included. Median OS and PFS were 9 (CI95% [3-10]) and 4 months (CI95% [2-13]) for R-GEMOX, 4 (CI95% [2-6]) and 1 month (CI95% [1-4]) for R-IE and 5 (CI95% [3-6]) and 3 months (CI95% [2-15]) for R-CEPP, respectively. Univariate analysis selects ECOG, aa-IPI scores, LDH rate and Ann-Arbor stage with no independently association in multivariate analysis.

Conclusion: All three regimens show modest survival benefit especially between last anticancer treatment course and death. Emergence of bispecific antibodies and Cart-cells for which real-life benefits have yet to be demonstrated could be coupled with improved access to early palliative care.

{"title":"Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL).","authors":"Baptiste Fulbert, Théo Vincent, Justine Clarenne, Imman Abdelouahab, Antoine Le Bozec, Eric Durot, Florian Slimano","doi":"10.1177/10781552241313381","DOIUrl":"https://doi.org/10.1177/10781552241313381","url":null,"abstract":"<p><strong>Background: </strong>Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for Hematopoietic Stem Cell Transplantation (HSCT) may benefit from a second line anticancer drug regimen but real-life outcomes are lacking.</p><p><strong>Objective: </strong>To describe the efficacity of 3 anticancer drug regimens (Gemcitabine and Oxaliplatin GEMOX; Ifosfamide and Etoposide IE; Cyclophosphamide, Etoposide, Procarbazine and Prednisone CEPP) combined with Rituximab (R-) in terms of progression-free (PFS) and overall survival (OS).</p><p><strong>Patients: </strong>Retrospective study including R/R DLBCL patients HSCT ineligible who received at least one cycle of R-GEMOX, R-IE or R-CEPP between 2010 and 2022. Demographic, clinical, biological and survival data were collected. Univariate and multivariate analysis were performed to identify associated variables with survival outcomes.</p><p><strong>Results: </strong>Sixty-two patients (median age 78 [40-102] with predominantly stage III-IV DLBCL (n = 49, 79%), non-germinal center-B like (n = 27, 44%) were included. Median OS and PFS were 9 (CI95% [3-10]) and 4 months (CI95% [2-13]) for R-GEMOX, 4 (CI95% [2-6]) and 1 month (CI95% [1-4]) for R-IE and 5 (CI95% [3-6]) and 3 months (CI95% [2-15]) for R-CEPP, respectively. Univariate analysis selects ECOG, aa-IPI scores, LDH rate and Ann-Arbor stage with no independently association in multivariate analysis.</p><p><strong>Conclusion: </strong>All three regimens show modest survival benefit especially between last anticancer treatment course and death. Emergence of bispecific antibodies and Cart-cells for which real-life benefits have yet to be demonstrated could be coupled with improved access to early palliative care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241313381"},"PeriodicalIF":1.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care - a literature review.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-03 DOI: 10.1177/10781552251316827
Haneen Badreldin Ali, Ujunwa P Dike, Muhammad Burhan Khan, Naiba Khusrau

Cancer presents significant physical and mental challenges to patients. Therefore, psychological assessment is important following a cancer diagnosis, as well as during and after chemotherapy. In cancer treatment, the goal of healthcare providers, including pharmacists, should be to deliver holistic care that addresses important aspects of patients' health, with particular emphasis on their psychological readiness to combat their diseases. This article reviews published literature from Google Scholar and PubMed to examine the relevant pharmacotherapy and psychotherapy approaches to managing psychological issues in cancer patients. This article also discusses how pharmacists can be integrated into cancer patients' mental health care, while highlighting the potential benefits and challenges associated with this approach. We conclude that the integration of pharmacists into psychological care and support for cancer patients holds promise due to their knowledge of cancer chemotherapy, their ability to improve their knowledge about psychological care, and their capacity to collaborate with other healthcare professionals in cancer treatment.

{"title":"Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care - a literature review.","authors":"Haneen Badreldin Ali, Ujunwa P Dike, Muhammad Burhan Khan, Naiba Khusrau","doi":"10.1177/10781552251316827","DOIUrl":"https://doi.org/10.1177/10781552251316827","url":null,"abstract":"<p><p>Cancer presents significant physical and mental challenges to patients. Therefore, psychological assessment is important following a cancer diagnosis, as well as during and after chemotherapy. In cancer treatment, the goal of healthcare providers, including pharmacists, should be to deliver holistic care that addresses important aspects of patients' health, with particular emphasis on their psychological readiness to combat their diseases. This article reviews published literature from Google Scholar and PubMed to examine the relevant pharmacotherapy and psychotherapy approaches to managing psychological issues in cancer patients. This article also discusses how pharmacists can be integrated into cancer patients' mental health care, while highlighting the potential benefits and challenges associated with this approach. We conclude that the integration of pharmacists into psychological care and support for cancer patients holds promise due to their knowledge of cancer chemotherapy, their ability to improve their knowledge about psychological care, and their capacity to collaborate with other healthcare professionals in cancer treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316827"},"PeriodicalIF":1.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antifungal-drug interactions in oncology: A cross-sectional study highlighting the role of pharmacists.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-29 DOI: 10.1177/10781552251316184
Zunaira Akbar, Muhammad Aamir, Zikria Saleem, Muhammad Rehan Khan

Study objective: Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.

Methodology: A retrospective, cross-sectional study was conducted to identify antifungal drug interactions over the period of 5 years (2019-2023) among cancer patients. Electronic medical record of 384 hospitalized patients receiving systemic antifungal therapy were reviewed. Severity of interactions and risk classification were made using UptoDate® LexidrugTM software. Pharmacists' recommendations regarding DDIs were also documented. Descriptive statistics and logistic regression were applied to interpret results.

Results: Antifungals were more frequently prescribed to adult patients (53.9%). Female cancer patients were significantly more likely to encounter DDIs than males (p < 0.003). Type of cancer and fungal infections were significantly associated with incidence of DDIs (p < 0.01; p = 0.000). Pharmacist identified DDIs in 53.9% antifungal prescriptions with 22.2% classified as major interactions. A substantial proportion of these interactions involved voriconazole (40.1%). Majority of pharmacist's recommendations included dose optimization of voriconazole (10.4%), close monitoring of RFTs (8.9%) and withholding amphotericin (5.2%) during chemotherapy. All of the recommendations made by pharmacists were accepted by physicians (100%).

Conclusion: The findings indicate that pharmacists identified DDIs in 53.9% of prescriptions and all of their recommendations were accepted by physicians. This highlights the critical role of pharmacists in detecting potential interactions, ensuring medication safety, and minimizing adverse effects associated with complex pharmacotherapy.

{"title":"Antifungal-drug interactions in oncology: A cross-sectional study highlighting the role of pharmacists.","authors":"Zunaira Akbar, Muhammad Aamir, Zikria Saleem, Muhammad Rehan Khan","doi":"10.1177/10781552251316184","DOIUrl":"https://doi.org/10.1177/10781552251316184","url":null,"abstract":"<p><strong>Study objective: </strong>Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.</p><p><strong>Methodology: </strong>A retrospective, cross-sectional study was conducted to identify antifungal drug interactions over the period of 5 years (2019-2023) among cancer patients. Electronic medical record of 384 hospitalized patients receiving systemic antifungal therapy were reviewed. Severity of interactions and risk classification were made using UptoDate<sup>®</sup> Lexidrug<sup>TM</sup> software. Pharmacists' recommendations regarding DDIs were also documented. Descriptive statistics and logistic regression were applied to interpret results.</p><p><strong>Results: </strong>Antifungals were more frequently prescribed to adult patients (53.9%). Female cancer patients were significantly more likely to encounter DDIs than males (<i>p </i>< 0.003). Type of cancer and fungal infections were significantly associated with incidence of DDIs (<i>p </i>< 0.01; <i>p </i>= 0.000). Pharmacist identified DDIs in 53.9% antifungal prescriptions with 22.2% classified as major interactions. A substantial proportion of these interactions involved voriconazole (40.1%). Majority of pharmacist's recommendations included dose optimization of voriconazole (10.4%), close monitoring of RFTs (8.9%) and withholding amphotericin (5.2%) during chemotherapy. All of the recommendations made by pharmacists were accepted by physicians (100%).</p><p><strong>Conclusion: </strong>The findings indicate that pharmacists identified DDIs in 53.9% of prescriptions and all of their recommendations were accepted by physicians. This highlights the critical role of pharmacists in detecting potential interactions, ensuring medication safety, and minimizing adverse effects associated with complex pharmacotherapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316184"},"PeriodicalIF":1.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted therapy in TNBC: Exploring the role of antibody-drug conjugates with a focus on sacituzumab govitecan.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-28 DOI: 10.1177/10781552251316433
Nahida Siddiqui, Moduru Tejo Arun, Kummari Aparna, Madishetti Abhishek Murthy, Tadikonda Rama Rao

Objectives: To underscore the prevalence and mortality of breast cancer and review advancements in metastatic TNBC management, with a particularly focus on the role of antibody-drug conjugates (ADCs), emphasizing the safety and therapeutic potential of Sacituzumab govitecan (SG) as a groundbreaking ADC.

Data sources: This review gathers scientific data from the past decade, sourced from PUBMED, ClinicalTrials.gov, and Google Scholar to retrieve relevant studies focused on SG in metastatic TNBC treatment.

Data summary: Breast cancer is the most common cancer in women, with TNBC being particularly aggressive and difficult to treat. Recent advancements, such as ADCs, have enhanced treatment options. The third-generation Trop-2-targeting ADC, SG, shows promise for metastatic TNBC. This review summarizes available scientific data on SG's safety, efficacy, and future potential. It also discusses ongoing clinical trials evaluating SG in various combinations, offering hope for improved therapeutic strategies in this high-risk group.

Conclusions: ADCs hold great promise for transforming anti-tumor therapies over the next decade and SG has demonstrated substantial efficacy and a manageable safety profile in treating metastatic TNBC. Ongoing trials show that combining SG with immunotherapies enhances its potential, offering hope for better outcomes in patients with limited options. These findings highlight the need for further research to fully define SG's role in optimizing treatment strategies.

目的:强调乳腺癌的发病率和死亡率,回顾转移性TNBC治疗的进展,尤其关注抗体药物共轭物(ADC)的作用,强调萨库珠单抗-戈维替康(SG)作为一种开创性ADC的安全性和治疗潜力:本综述收集了过去十年的科学数据,数据来源于PUBMED、ClinicalTrials.gov和Google Scholar,以检索SG在转移性TNBC治疗中的相关研究。数据摘要:乳腺癌是女性最常见的癌症,TNBC尤其具有侵袭性且难以治疗。ADCs 等最新技术的进步增强了治疗方案的选择性。第三代Trop-2靶向ADC SG有望治疗转移性TNBC。本综述总结了有关 SG 的安全性、有效性和未来潜力的现有科学数据。它还讨论了正在进行的临床试验,这些试验评估了 SG 的各种组合,为改善这一高风险群体的治疗策略带来了希望:ADC有望在未来十年内改变抗肿瘤疗法,而SG在治疗转移性TNBC方面已显示出巨大的疗效和可控的安全性。正在进行的试验表明,将 SG 与免疫疗法相结合可增强其潜力,为选择有限的患者带来更好的治疗效果。这些发现凸显了进一步研究的必要性,以充分确定 SG 在优化治疗策略中的作用。
{"title":"Targeted therapy in TNBC: Exploring the role of antibody-drug conjugates with a focus on sacituzumab govitecan.","authors":"Nahida Siddiqui, Moduru Tejo Arun, Kummari Aparna, Madishetti Abhishek Murthy, Tadikonda Rama Rao","doi":"10.1177/10781552251316433","DOIUrl":"https://doi.org/10.1177/10781552251316433","url":null,"abstract":"<p><strong>Objectives: </strong>To underscore the prevalence and mortality of breast cancer and review advancements in metastatic TNBC management, with a particularly focus on the role of antibody-drug conjugates (ADCs), emphasizing the safety and therapeutic potential of Sacituzumab govitecan (SG) as a groundbreaking ADC.</p><p><strong>Data sources: </strong>This review gathers scientific data from the past decade, sourced from PUBMED, ClinicalTrials.gov, and Google Scholar to retrieve relevant studies focused on SG in metastatic TNBC treatment.</p><p><strong>Data summary: </strong>Breast cancer is the most common cancer in women, with TNBC being particularly aggressive and difficult to treat. Recent advancements, such as ADCs, have enhanced treatment options. The third-generation Trop-2-targeting ADC, SG, shows promise for metastatic TNBC. This review summarizes available scientific data on SG's safety, efficacy, and future potential. It also discusses ongoing clinical trials evaluating SG in various combinations, offering hope for improved therapeutic strategies in this high-risk group.</p><p><strong>Conclusions: </strong>ADCs hold great promise for transforming anti-tumor therapies over the next decade and SG has demonstrated substantial efficacy and a manageable safety profile in treating metastatic TNBC. Ongoing trials show that combining SG with immunotherapies enhances its potential, offering hope for better outcomes in patients with limited options. These findings highlight the need for further research to fully define SG's role in optimizing treatment strategies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316433"},"PeriodicalIF":1.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication-related osteonecrosis of the jaw in patients with cancer using zoledronic acid and denosumab: Single-center retrospective study.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-28 DOI: 10.1177/10781552251316440
Motohiko Sano, Mai Amano, Miki Yamada, Yosuke Iijima, Shunsuke Hino, Hiroshi Sakagami, Norio Horie, Takahiro Kaneko

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially severe condition that significantly affects the quality of life of patients with cancer. This study evaluated MRONJ in patients with cancer treated with zoledronic acid (ZOA) and denosumab (Dmab).

Methods: The survey investigated patients who were diagnosed with MRONJ at the Department of Oral and Maxillofacial Surgery after receiving either ZOA or Dmab at the Saitama Medical Center, Saitama Medical University, between April 1, 2022, and March 31, 2023.

Results: Of 252 patients, 27 were ZOA users and 225 were Dmab users. MRONJ was not observed with ZOA. MRONJ was detected in 11 (4.9%) Dmab users, eight male and three female patients with a mean (± standard deviation) age of 74.6 (± 9.2) years (range 61-98 years). The total dose of Dmab was 2724 ± 1838 mg (range: 480-6360 mg). The time from Dmab administration to MRONJ onset was 28.0 ± 16.0 months (range 4.5-53.2 months). Of the 11 patients with MRONJ, four (36.4%) had visited a dentist within the last 12 months. One participant (9.1%) was informed about and understood MRONJ.

Conclusions: MRONJ was only observed in Dmab users, with an incidence rate of 4.9%. The percentage of patients with MRONJ receiving regular dental check-ups was 36.4%, and only 9.1% of patients were aware of MRONJ, both of which are low rates. To reduce MRONJ in patients with cancer, face-to-face consultations with pharmacists could serve as a valuable opportunity to inform patients about MRONJ and encourage regular dental visits.

{"title":"Medication-related osteonecrosis of the jaw in patients with cancer using zoledronic acid and denosumab: Single-center retrospective study.","authors":"Motohiko Sano, Mai Amano, Miki Yamada, Yosuke Iijima, Shunsuke Hino, Hiroshi Sakagami, Norio Horie, Takahiro Kaneko","doi":"10.1177/10781552251316440","DOIUrl":"https://doi.org/10.1177/10781552251316440","url":null,"abstract":"<p><strong>Background: </strong>Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially severe condition that significantly affects the quality of life of patients with cancer. This study evaluated MRONJ in patients with cancer treated with zoledronic acid (ZOA) and denosumab (Dmab).</p><p><strong>Methods: </strong>The survey investigated patients who were diagnosed with MRONJ at the Department of Oral and Maxillofacial Surgery after receiving either ZOA or Dmab at the Saitama Medical Center, Saitama Medical University, between April 1, 2022, and March 31, 2023.</p><p><strong>Results: </strong>Of 252 patients, 27 were ZOA users and 225 were Dmab users. MRONJ was not observed with ZOA. MRONJ was detected in 11 (4.9%) Dmab users, eight male and three female patients with a mean (± standard deviation) age of 74.6 (± 9.2) years (range 61-98 years). The total dose of Dmab was 2724 ± 1838 mg (range: 480-6360 mg). The time from Dmab administration to MRONJ onset was 28.0 ± 16.0 months (range 4.5-53.2 months). Of the 11 patients with MRONJ, four (36.4%) had visited a dentist within the last 12 months. One participant (9.1%) was informed about and understood MRONJ.</p><p><strong>Conclusions: </strong>MRONJ was only observed in Dmab users, with an incidence rate of 4.9%. The percentage of patients with MRONJ receiving regular dental check-ups was 36.4%, and only 9.1% of patients were aware of MRONJ, both of which are low rates. To reduce MRONJ in patients with cancer, face-to-face consultations with pharmacists could serve as a valuable opportunity to inform patients about MRONJ and encourage regular dental visits.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316440"},"PeriodicalIF":1.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and predictive factors of chemotherapy-induced peripheral neuropathy in cancer patients: A cross-sectional single-center study in Pakistan.
IF 1 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-26 DOI: 10.1177/10781552251314348
Ismail Jadoon, Muhammad Arfat Yameen

Chemotherapy-induced peripheral neuropathy is a debilitating pain condition resulting from cancer treatment and is known to be associated with a decrease in health-related quality of life. This single-center cross-sectional study, conducted at Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Abbottabad, Pakistan, assessed the prevalence and severity of chemotherapy-induced peripheral neuropathy and its impact on quality of life in cancer patients undergoing chemotherapy. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-CIPN20 questionnaires. Subscales are scored from 0 to 100, with higher scores indicating greater symptom severity. A total of 154 patients participated, with a mean age of 48.57 years (SD 14.22); 33.8% were male and 66.2% were female. The prevalence of sensory CIPN was 36.4%. The mean scores for the sensory, motor, and autonomic subscales of the QLQ-CIPN20 were 23.2 (SD 19.1), 16.6 (SD 15.8), and 14.8 (SD 17.2), respectively. CIPN symptom severity was negatively correlated with global health status/quality of life and physical, role, emotional, cognitive, and social functioning. There was no significant association with age, sex, body surface area, height, weight, or type of chemotherapeutic agent used. However, symptom severity increased with the number of treatment cycles completed (e.g., sensory, p = 0.003). CIPN was prevalent in this healthcare center and significantly impacted function and quality of life. These findings highlight the importance of developing strategies to mitigate CIPN and the need for routine screening of CIPN.

{"title":"Prevalence and predictive factors of chemotherapy-induced peripheral neuropathy in cancer patients: A cross-sectional single-center study in Pakistan.","authors":"Ismail Jadoon, Muhammad Arfat Yameen","doi":"10.1177/10781552251314348","DOIUrl":"https://doi.org/10.1177/10781552251314348","url":null,"abstract":"<p><p>Chemotherapy-induced peripheral neuropathy is a debilitating pain condition resulting from cancer treatment and is known to be associated with a decrease in health-related quality of life. This single-center cross-sectional study, conducted at Institute of Nuclear Medicine Oncology and Radiotherapy (INOR), Abbottabad, Pakistan, assessed the prevalence and severity of chemotherapy-induced peripheral neuropathy and its impact on quality of life in cancer patients undergoing chemotherapy. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-CIPN20 questionnaires. Subscales are scored from 0 to 100, with higher scores indicating greater symptom severity. A total of 154 patients participated, with a mean age of 48.57 years (SD 14.22); 33.8% were male and 66.2% were female. The prevalence of sensory CIPN was 36.4%. The mean scores for the sensory, motor, and autonomic subscales of the QLQ-CIPN20 were 23.2 (SD 19.1), 16.6 (SD 15.8), and 14.8 (SD 17.2), respectively. CIPN symptom severity was negatively correlated with global health status/quality of life and physical, role, emotional, cognitive, and social functioning. There was no significant association with age, sex, body surface area, height, weight, or type of chemotherapeutic agent used. However, symptom severity increased with the number of treatment cycles completed (e.g., sensory, <i>p </i>= 0.003). CIPN was prevalent in this healthcare center and significantly impacted function and quality of life. These findings highlight the importance of developing strategies to mitigate CIPN and the need for routine screening of CIPN.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251314348"},"PeriodicalIF":1.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Oncology Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1